Mark Anthony Mccamish has sold stock and made no open-market buys since Dec 2018

Dr. Mark Anthony McCamish is a biotechnology executive and corporate director who serves on the Board of Directors of Avadel Pharmaceuticals plc (AVDL), where he has been a director since December 2019.( As an Avadel insider, he holds both direct and indirect positions in the company’s ordinary shares and has reported multiple transactions, including sales and trust-related transfers, through SEC Form 4 filings.( His holdings and trading activity are recorded under his SEC Central Index Key (CIK) 0001390798.(

Beyond Avadel, McCamish has accumulated equity positions across several life-science companies, including Facet Biotech Corp, Vincera Pharma, Rafael Holdings, Forty Seven Inc., and PDL BioPharma, reflecting a long career in senior roles within the pharmaceutical and biotechnology sectors.( Public filings and board databases identify him as Dr. Mark A. McCamish, indicating an advanced scientific or medical training background, and he has been active as a corporate insider for many years, with 2019 noted as his most active year for share acquisitions.( His current professional profile combines board service, executive leadership experience in biotech, and ongoing governance responsibilities in the pharmaceutical industry.(

Written by Perplexity from public sources.